Selecting initial therapy for invasive breast cancer

Marc E Lippman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The correct choice of therapy for localized breast cancer in contraversial. A great many published clinical experiences, some of considerable size, have tended on the one hand to provide apparently contradictory information, and on the other hand to polarize views. A detailed consideration of the many clinical, pathologic, biochemical and kinetic prognostic variables which may bias such clinical experiences will be discussed. These may contribute to differing results from institutions apparently employing a single treatment plan. The prospectively randomized trials which have helped to establish the limits of acceptable therapy for localized breast cancer will also be reviewed together with comments on their limitations. Particular attention will be paid to National Surgical Adjuvant Breast Project (NSABP) trial B-06; the Milan Cancer Institute trial; and current National Cancer Institute (NCI) investigations. A thorough consideration of these issues should permit a more rational choice of primary treatment for patients with Stage I and Stage II breast cancer.

Original languageEnglish
Pages (from-to)2050-2053
Number of pages4
JournalCancer
Volume60
Issue number8 SUPPl.
StatePublished - Dec 1 1987
Externally publishedYes

Fingerprint

Breast Neoplasms
National Cancer Institute (U.S.)
Therapeutics
Breast
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lippman, M. E. (1987). Selecting initial therapy for invasive breast cancer. Cancer, 60(8 SUPPl.), 2050-2053.

Selecting initial therapy for invasive breast cancer. / Lippman, Marc E.

In: Cancer, Vol. 60, No. 8 SUPPl., 01.12.1987, p. 2050-2053.

Research output: Contribution to journalArticle

Lippman, ME 1987, 'Selecting initial therapy for invasive breast cancer', Cancer, vol. 60, no. 8 SUPPl., pp. 2050-2053.
Lippman ME. Selecting initial therapy for invasive breast cancer. Cancer. 1987 Dec 1;60(8 SUPPl.):2050-2053.
Lippman, Marc E. / Selecting initial therapy for invasive breast cancer. In: Cancer. 1987 ; Vol. 60, No. 8 SUPPl. pp. 2050-2053.
@article{d50d1b6d553348dabb1595014044500d,
title = "Selecting initial therapy for invasive breast cancer",
abstract = "The correct choice of therapy for localized breast cancer in contraversial. A great many published clinical experiences, some of considerable size, have tended on the one hand to provide apparently contradictory information, and on the other hand to polarize views. A detailed consideration of the many clinical, pathologic, biochemical and kinetic prognostic variables which may bias such clinical experiences will be discussed. These may contribute to differing results from institutions apparently employing a single treatment plan. The prospectively randomized trials which have helped to establish the limits of acceptable therapy for localized breast cancer will also be reviewed together with comments on their limitations. Particular attention will be paid to National Surgical Adjuvant Breast Project (NSABP) trial B-06; the Milan Cancer Institute trial; and current National Cancer Institute (NCI) investigations. A thorough consideration of these issues should permit a more rational choice of primary treatment for patients with Stage I and Stage II breast cancer.",
author = "Lippman, {Marc E}",
year = "1987",
month = "12",
day = "1",
language = "English",
volume = "60",
pages = "2050--2053",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8 SUPPl.",

}

TY - JOUR

T1 - Selecting initial therapy for invasive breast cancer

AU - Lippman, Marc E

PY - 1987/12/1

Y1 - 1987/12/1

N2 - The correct choice of therapy for localized breast cancer in contraversial. A great many published clinical experiences, some of considerable size, have tended on the one hand to provide apparently contradictory information, and on the other hand to polarize views. A detailed consideration of the many clinical, pathologic, biochemical and kinetic prognostic variables which may bias such clinical experiences will be discussed. These may contribute to differing results from institutions apparently employing a single treatment plan. The prospectively randomized trials which have helped to establish the limits of acceptable therapy for localized breast cancer will also be reviewed together with comments on their limitations. Particular attention will be paid to National Surgical Adjuvant Breast Project (NSABP) trial B-06; the Milan Cancer Institute trial; and current National Cancer Institute (NCI) investigations. A thorough consideration of these issues should permit a more rational choice of primary treatment for patients with Stage I and Stage II breast cancer.

AB - The correct choice of therapy for localized breast cancer in contraversial. A great many published clinical experiences, some of considerable size, have tended on the one hand to provide apparently contradictory information, and on the other hand to polarize views. A detailed consideration of the many clinical, pathologic, biochemical and kinetic prognostic variables which may bias such clinical experiences will be discussed. These may contribute to differing results from institutions apparently employing a single treatment plan. The prospectively randomized trials which have helped to establish the limits of acceptable therapy for localized breast cancer will also be reviewed together with comments on their limitations. Particular attention will be paid to National Surgical Adjuvant Breast Project (NSABP) trial B-06; the Milan Cancer Institute trial; and current National Cancer Institute (NCI) investigations. A thorough consideration of these issues should permit a more rational choice of primary treatment for patients with Stage I and Stage II breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023627591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023627591&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 2050

EP - 2053

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8 SUPPl.

ER -